 |
May 9, 2013
Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/09/13 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences:
BofA Merrill Lynch 2013 Healthcare Conference, May 15, 2013, ...
|
|
May 2, 2013
Threshold Pharmaceuticals Reports First Quarter 2013 Financial and Operational Results |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/02/13 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the first quarter 2013. Revenue for the first quarter ended March 31, 2013 was $2.9 million. The operating loss for the first quarter ended March 31, 2013 was $6.1 million. The net loss for the first quart...
|
|
Apr 25, 2013
Threshold Pharmaceuticals Announces Presentation and Webcast at the 12th Annual Needham Healthcare Conference |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/25/13 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 12th Annual Needham Healthcare Conference on April 30, 2013, at 1:40 p.m. ET.
A live webcast of the presentation w...
|
|
Apr 1, 2013
Threshold Pharmaceuticals Announces Presentation and Webcast at the 20th Annual Future Leaders in the Biotech Industry Conference |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/01/13 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 20th Annual Future Leaders in the Biotechnology Industry Conference at 8:30 a.m. ET on Friday, April 5, 2013.
A...
|
|
Mar 21, 2013
Threshold Announces Acquisition of Investigational Hypoxia PET Imaging Agent [18F]HX4 From Siemens |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/21/13 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced a global agreement with Siemens Healthcare to acquire its investigational agent [18F]HX4 [flortanidazole (18F)], a radiolabeled hypoxia Positron Emission Tomography (PET) tracer. [18F]HX4 could potentially be used as a companion...
|
|
Mar 7, 2013
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial and Operational Results |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/07/13 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2012 and provided a clinical outlook related to the development of TH-302, the company's lead investigational hypoxia-targeted drug currently in pivotal Phase ...
|
|
Feb 26, 2013
Threshold Pharmaceuticals Announces Presentation and Webcast at Cowen and Company's 33rd Annual Health Care Conference |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/26/13 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at Cowen and Company's 33rd Annual Health Care Conference at 2:10 p.m. ET on Monday, March 4, 2013.
A live webcast of ...
|
|
Jan 25, 2013
Threshold Pharmaceuticals Announces Initiation of TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/25/13 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase 3 MAESTRO study assessing the efficacy and safety of investigational hypoxia-targeted drug TH-302 in combina...
|
|
Dec 10, 2012
Threshold Pharmaceuticals Announces Presentation and Webcast at Oppenheimer 23rd Annual Healthcare Conference |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/10/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Oppenheimer 23rd Annual Healthcare Conference at 3:20 p.m. ET on Thursday, December 13, 2012.
A live webcast o...
|
|
Nov 15, 2012
Threshold Pharmaceuticals Reports Updated Phase 2 Results Including Analyses of Maintenance Therapy With TH-302 Following Induction Therapy With TH-302 Plus Doxorubicin in Soft Tissue Sarcoma |
| |
PRAGUE, CZECH REPUBLIC -- (Marketwire) -- 11/15/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced updated results from a Phase 2 study of TH-302, the company's investigational hypoxia-targeted drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent ma...
|
|
Nov 7, 2012
Threshold Pharmaceuticals Announces Presentation and Webcast at Lazard Capital Markets 9th Annual Healthcare Conference |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/07/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Lazard Capital Markets 9th Annual Healthcare Conference at 2:00 p.m. ET on Wednesday, November 14, 2012.
A liv...
|
|
Nov 2, 2012
Threshold Pharmaceuticals Reports Third Quarter 2012 Financial and Operational Results |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/02/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter ended September 30, 2012. Revenue for the third quarter ended September 30, 2012 was $1.8 million. The operating loss for the third quarter ended September 30, 2012 was $4.0 million. The ne...
|
|
Oct 16, 2012
Threshold Pharmaceuticals Announces Agreement With U.S. FDA on a Special Protocol Assessment for Planned Phase 3 Trial of TH-302 in Combination With Gemcitabine in Advanced Pancreatic Cancer |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 10/16/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) has reached agreement with the U.S. affiliate of Merck KGaA, Darmstadt, Germany, Threshold's partner for the development and commercialization of TH-302, covering a Special Proto...
|
|
Oct 4, 2012
Threshold Pharmaceuticals Announces Presentation and Webcast at 11th Annual BIO Investor Forum |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 10/04/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 11th Annual BIO Investor Forum at 2:30 p.m. PT on October 10, 2012, taking place in San Francisco, CA.
A record...
|
|
Sep 30, 2012
Threshold Pharmaceuticals Announces Preliminary Data From Phase 1/2 Study of TH-302 in Combination With Bevacizumab in Patients With Recurrent Glioblastoma |
| |
VIENNA, AUSTRIA -- (Marketwire) -- 09/30/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced preliminary data from an ongoing dose-escalation Phase 1/2 clinical trial of its investigational hypoxia-targeted drug TH-302 in combination with bevacizumab in patients with recurrent glioblastoma. No dose-limiting toxicity has been r...
|
|
Sep 26, 2012
Threshold Pharmaceuticals Announces Presentations on TH-302 in Pancreatic Cancer and Glioblastoma at ESMO |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/26/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that clinical data on its investigational hypoxia-targeted drug, TH-302, will be highlighted in two presentations during the European Society for Medical Oncology (ESMO) 2012 Congress taking place September 28 - October 2, 2012...
|
|
Sep 19, 2012
Threshold Pharmaceuticals Announces Presentation and Webcast at BIOX, Noble Financial Capital Markets' Life Sciences Exposition |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/19/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Charles P. Hart, Ph.D., Threshold's Vice President of Biology, will present an overview of the company's targeted tumor hypoxia platform at BIOX, Noble Financial Capital Markets' Life Sciences Exposition, to be held at the...
|
|
Sep 18, 2012
Threshold Pharmaceuticals Announces Presentation and Webcast at UBS Global Life Sciences Conference |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/18/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the UBS Global Life Sciences Conference at 8:30 a.m. ET on September 19, 2012.
A live webcast of the presentation w...
|
|
Sep 17, 2012
Threshold Pharmaceuticals to Present Updated Data From Phase 2b Clinical Trial of TH-302 in Combination With Gemcitabine in Advanced Pancreatic Cancer at ESMO 2012 Congress |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/17/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that data from a randomized open-label Phase 2b clinical trial of investigational hypoxia-targeted drug TH-302 in patients with advanced pancreatic cancer will be presented at the European Society for Medical Oncology (ESMO) 201...
|
|
Aug 29, 2012
Threshold Pharmaceuticals Announces Presentations and Webcasts at Two Upcoming Investor Conferences |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 08/29/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that corporate presentations will be webcast during two upcoming investor meetings: Stifel Nicolaus 2012 Healthcare Conference in Boston and NewsMakers in the Biotech Industry in New York.
Barry Selick, Ph.D., Thr...
|
|
|
